help button home button Endocrine Society JCEM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Journal of Clinical Endocrinology & Metabolism , doi:10.1210/jc.2004-2490
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Submit a related Letter to the Editor
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Gambineri, A.
Right arrow Articles by Pasquali, R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Gambineri, A.
Right arrow Articles by Pasquali, R.
Related Collections
Right arrow Female Endocrinology
Right arrow Obesity
The Journal of Clinical Endocrinology & Metabolism Vol. 90, No. 7 3854-3862
Copyright © 2005 by The Endocrine Society

Efficacy of Octreotide-LAR in Dieting Women with Abdominal Obesity and Polycystic Ovary Syndrome

Alessandra Gambineri, Laura Patton, Rosaria De Iasio, Barbara Cantelli, Graciela Estela Cognini, Marco Filicori, Antonina Barreca1, Evanthia Diamanti-Kandarakis, Uberto Pagotto and Renato Pasquali

Division of Endocrinology, Department of Internal Medicine, and Center for Applied Biomedical Research, S. Orsola-Malpighi Hospital (A.G., L.P., R.D.I., U.P., R.P.), and Reproductive Endocrinology Center (B.C., G.E.C., M.F.), University of Bologna, 40138 Bologna, Italy; Department of Endocrinological and Metabolic Sciences and Center for Excellence for Biomedical Research, University of Genova (A.B.), 16132 Genova, Italy; and Endocrine Section, First Department of Internal Medicine, Athens University School of Medicine, Laiko General Hospital (E.D.-K.), 17562 Athens, Greece

Address all correspondence and requests for reprints to: Dr. Renato Pasquali, Division of Endocrinology, Department of Internal Medicine, S. Orsola-Malpighi Hospital, Via Massarenti 9, 40138 Bologna, Italy. E-mail: renato.pasquali{at}unibo.it.


   Abstract
Top
 Abstract
Introduction
 Subjects and Methods
 Results
 Discussion
 References
 
Context: Somatostatin reduces LH, GH, and insulin, and somatostatin receptors are present at the ovarian level; somatostatin analogs are thus potential candidates for treatment of the polycystic ovary syndrome (PCOS).

Objective: The purpose of this study was to evaluate the effect of octreotide-LAR, a long-acting somatostatin analog, in anovulatory abdominal obese women with PCOS.

Design: A single-blind, placebo-controlled study was performed, lasting for 7 months.

Setting: The patients were ambulatory throughout the study.

Patients: Twenty PCOS subjects were enrolled. Eighteen completed the study.

Interventions: A low-calorie diet was given during the first month, a low-calorie diet plus octreotide-LAR (10 mg; n = 10 subjects) or placebo (n = 10 subjects) was then given, with one im injection every 28 d (for 6 months).

Main Outcome Measures: The main outcome measures were clinical features, computerized tomography measurement of fat distribution, androgens, GH, IGF-I, IGF-binding proteins (IGFBPs), fasting and glucose-stimulated insulin, and ovulation.

Results: Octreotide had no additional effect in reducing body fat or improving fat distribution than placebo. Conversely, octreotide produced an additional decrease in fasting (P = 0.018) and glucose-stimulated (P = 0.038) insulin levels, an increase in IGFBP-2 (P = 0.042) and IGFBP-3 (P = 0.047), and an improvement in hirsutism (P = 0.004). Moreover, a trend toward greater reductions in testosterone (P = 0.061) and androstenedione (P = 0.069) was observed in women treated with octreotide-LAR compared with those given placebo. All women treated with octreotide ovulated at the end of the study compared with only one of those receiving placebo (P < 0.001).

Conclusions: Octreotide-LAR may be usefully applied to hypocalorically dieting, abdominal obese PCOS women to improve hyperandrogenism and the insulin-IGF-I system. Restoration of ovulatory menstrual cycles appears to be another advantage of this treatment.


   Introduction
Top
 Abstract
 Introduction
Subjects and Methods
 Results
 Discussion
 References
 
THE POLYCYSTIC OVARY syndrome (PCOS) is a complex and heterogeneous disorder whose cardinal features are hyperandrogenism and chronic oligo-anovulation (1). However, most PCOS patients, particularly those with an abdominal obesity phenotype (2), also present with insulin resistance, which is intimately related to the development and maintenance of the syndrome (2). Hyperinsulinemia, the consequence of the insulin resistance state, is directly involved in determining an increase in androgen availability in peripheral target tissues by stimulating ovarian and adrenal steroidogenesis and decreasing hepatic SHBG synthesis (2). Although elevated LH concentrations, due to increased pituitary sensitivity to GnRH stimulation, represent one of the alternative mechanisms responsible for increased ovarian steroidogenesis, insulin synergizes with LH at the ovarian level, thus favoring excess thecal cell androgen production (1, 2). Moreover, insulin seems to increase the sensitivity of granulosa cells to FSH, and in this way, hyperinsulinemia may contribute to increase ovarian dimension and to favor the development of small antral follicles (3).

Hyperinsulinemia is considered one of the main factors involved in the pathogenesis of anovulation and infertility in PCOS women (4), as a consequence of an interaction with the IGF system (5). In particular, by suppressing hepatic and ovarian IGF-binding protein-1 (IGFBP-1) synthesis, insulin increases the bioavailability of the IGFs, therefore synergizing to stimulate ovarian steroidogenesis and to modulate ovarian follicle growth and apoptosis (5). The increased IGF availability observed in PCOS, however, seems to be differently determined in obese and normal weight subjects (6). In obese PCOS women, IGF-I alterations appear to be strictly related to the effects of hyperinsulinemia, whereas in normal weight PCOS women, they seem to be the consequence of increased pituitary secretion and relatively high circulating concentrations of GH (6). Therefore, the insulin-GH-IGF system appears to play a crucial role in the pathophysiology of PCOS.

Somatostatin is an endogenous hypothalamic peptide with a short half-life that, besides blunting the LH response to GnRH (7) and decreasing GH pituitary secretion (8), inhibits pancreatic insulin release (9). In addition, the recent discovery of somatostatin receptors at the adrenal (10) and ovary (11) levels suggests that these two organs may be under direct control of somatostatin. Preliminary studies by Prelevic and colleagues (12) showed that 7-d administration of octreotide, a synthetic somatostatin analog with a half-life of 80–110 min, improved pulsatile gonadotropin patterns, reduced androgen levels, and decreased fasting and glucose-stimulated insulin concentrations in PCOS women. More recently, a few other prospective, noncontrolled, short-term studies using octreotide expanded these findings (13, 14, 15, 16, 17, 18, 19, 20), showing that this compound not only reduced insulin, IGF-I, LH, and androgen levels (13, 14, 15, 16, 17, 18, 19, 20), but also increased spontaneous (13) and stimulated ovulation (14, 20) in PCOS patients. Unfortunately, the daily multiple sc injections required by the short life of octreotide makes this procedure inappropriate for a long-term treatment.

With this background, we carried out this placebo-controlled study to evaluate the effect of prolonged therapy with a long-acting somatostatin analog formulation (octreotide-LAR), injected im every 28 d, in a selected group of anovulatory PCOS women with abdominal obesity. Octreotide-LAR consists of octreotide acetate encapsulated with a biodegradable polymer (21). Its slow and constant drug release into the circulation makes it possible to improve patient compliance by avoiding repeated daily sc injections (21). An additional advantage of this formulation is a decreased occurrence of side effects, such as gallstone formation (21).


   Subjects and Methods
Top
 Abstract
 Introduction
 Subjects and Methods
Results
 Discussion
 References
 
Subjects

Twenty consecutive overweight or obese women with PCOS attending the Division of Endocrinology, Department of Internal Medicine, S. Orsola-Malpighi Hospital of Bologna were invited to participate in the study. No additional women were screened, because all invited women consented to participate after clinical examination and baseline blood tests were performed, and diagnosis was made. Their body mass index (BMI) values were greater than 28 kg/m2, and the waist to hip ratios were greater than 0.80, consistent with an abdominal fat distribution phenotype (22). The diagnosis of PCOS was made according to the presence of chronic anovulation [supported by luteal progesterone (P) measurement] (23), oligomenorrhea/amenorrhea, hirsutism (Ferriman-Gallwey score, ≥8) (24), or elevations in blood levels of total (T) and free (FAI) testosterone (25), and polycystic ovarian morphology at ultrasound (1). None had Cushing’s syndrome; late-onset congenital adrenal hyperplasia; hyperprolactinemia; thyroid dysfunction; diabetes; cardiovascular, renal, or liver disease; or gallstones. Moreover, no patient had taken any medication or significantly modified her body weight in the 3 months preceding the study, nor was any subject dieting.

Human chorionic gonadotropin was measured in each subject before the start of the study to exclude pregnancy. All women were also advised orally and in writing to use nonhormonal contraception throughout the study. The protocol was approved by the local ethics committee, and all women gave their informed and written consents to participate in the study.

Protocol study

At baseline, blood samples for hormonal and metabolic parameters were drawn between 0800 and 0830 h after overnight fasting, followed by an oral glucose tolerance test (OGTT; 75 g; Curvosio, Sclavo, Cinisello Balsamo, Italy). On the same day, an evaluation of anthropometric parameters (height, weight, and waist and hip circumferences), hirsutism, and acanthosis nigricans was performed. Hirsutism was estimated by the Ferriman-Gallwey score (24), whereas acanthosis nigricans was classified according to scale described in Ref. 26 . A computerized tomography (CT) scan measurement of body fat distribution was also performed at the level of L4–L5 to estimate total (TAT), visceral (VAT), and sc (SAT) adipose tissue areas (25). On the following day, all women were placed on a hypocaloric diet, ranging from 1200–1420 kcal/d, with 15% total proteins, 30% lipids, and 55% carbohydrates. All diets were prescribed by the same dietician, who calculated the dietary energy intake by subtracting 500 kcal from the usual individual energy intake. Habitual energy intake was calculated by means of the diet history method and a 3-d recall questionnaire. The women returned after 1 month for anthropometry and CT scan measurements. After this period and while continuing dietary treatment, PCOS women were scheduled to receive, in a random order and according to a single-blind design, octreotide-LAR (Novartis Farma S.p.A., Origgio-Varese, Italy; 10 mg; n = 10) or placebo (saline solution; n = 10), one im injection every 28 d for the following 6 months. The random allocation sequence to the two treatments was decided before the recruitment of the patients. Treatment with octreotide-LAR or placebo was preceded by 3 d of treatment with octreotide (Novartis Farma S.p.A.; 100 µg, sc, twice a day) or an equal amount of saline solution to test the individual tolerability to the drug. One investigator (L.P.) generated the random allocation sequence and administered the drugs (active or placebo) at the out-patient clinic for the entire period of the study, whereas another investigator (A.G.), blinded to group assignment, enrolled and regularly checked all patients at monthly intervals during the study to evaluate the appearance of side effects and tolerance to the treatments. The compliance with diet was evaluated by the same dietician at each visit, according to a previously defined method providing quantitative information on daily energy intake and macronutrient composition of the diet performed during the previous month. Patients failing to comply with dietary prescription (>30% excess kcal intake) were excluded from the study. Patients were also directed to maintain their usual physical activity, which was checked monthly by the self-administered questionnaire proposed by Baecke et al. (27). The frequency of menses during the study and in the 7 months previous to it were also evaluated and were expressed as menstrual status. At the end of the trial, a final examination was conducted by analyzing all measurements performed at baseline.

Finally, the occurrence of ovulation in each patient was monitored during both the first and the last menstrual cycle occurring during treatment with octreotide-LAR or placebo. Ovulation was assessed by performing pelvic ultrasound and by measuring serum levels of LH, FSH, estradiol (E2), and P at 7, 14, 21, and 28 d after the start of menstrual bleeding. Ovulation was assumed to have occurred when a dominant follicle with a diameter higher than 12 mm or a corpus luteum was seen on pelvic ultrasound scanning, and P and E2 concentrations were higher than 8 ng/ml and 100 pg/ml, respectively (23).

During the treatment period, two women in the placebo group were excluded because of noncompliance with the diet, one in the first and the other in the third month of treatment. The cohort available for final statistical analysis, therefore, included 18 PCOS women, 10 treated with octreotide-LAR and eight given placebo. A schematic representation of the study design is shown in Fig. 1Go.



View larger version (12K):
[in this window]
[in a new window]
  		FIG. 1. Study design.

 
Tolerance and side effects

To assess the tolerance and the appearance of side effects, a self-administered questionnaire was given, and a blood sample was obtained at each monthly visit. The questionnaire evaluated the presence of gastrointestinal disturbances, such as abdominal pain, abdominal swelling, flatulence, diarrhea, nausea, and vomiting, and the appearance of pain, swelling, and blushing at the site of the im injection. Blood tests included liver enzymes, bilirubin, and complete blood count. A gallbladder ultrasound was also performed at the start and the end of the study to detect any gallstone formation.

Assays

Blood samples were centrifuged immediately, and serum was stored at –20 C; plasma was kept at –80 C until assayed. Plasma glucose levels were determined by the glucose oxidase method. Insulin, LH, FSH, T, dehydroepiandrosterone sulfate (DHEA-S), E2, P, androstenedione (A), 17-hydroxyprogesterone (17-OHP), 17-hydroxypregnenolone (17-OHPreg), cortisol, SHBG, IGFBP-1, IGFBP-2, IGFBP-3, and total plasma ghrelin were measured as previously described (28, 29, 30). GH was measured by the immunochemiluminescence assay, and IGF-I was determined by immunoradiometric assay. FAI was calculated as the ratio between total T and SHBG (31). To investigate insulin sensitivity, the homeostasis model assessment (HOMA), the quantitative insulin-sensitivity check index (QUICKI), and the insulin sensitivity index during the OGTT [ISI(composite)] were calculated (32, 33, 34).

The intraassay coefficients of variation in our laboratory were 3.0% for insulin, 4.8% for LH, 1.9% for FSH, 7.0% for T, 5.9% for DHEA-S, 5.6% for E2, 4.1% for P, 6.0% for A, 13% for 17-OHP, 8% for 17-OHPreg, 10% for cortisol, 6.5% for SHBG, 2.5% for IGFBP-1, 6% for IGFBP-2, 3.25% for IGFBP-3, 5.3% for ghrelin, 5% for GH, and 6% for IGF-I.

Statistical analysis

Results were reported as the mean ± SD unless otherwise indicated. The responses of glucose and insulin to the OGTT were analyzed by calculating the area under the curve (AUC) by the trapezoidal method. A one-way ANOVA was applied to compare values between groups at baseline, whereas the repeated measure ANOVA was performed to estimate the within- and between-group modifications. The occurrence of ovulation and side effects and the tolerance to the treatments were analyzed by means of Fisher’s exact test (baseline values between groups), the McNemar test (modifications within groups), and the hierarchical log-linear models (modifications between groups). Statistical analyses were performed by running the SPSS/PC+ (SPSS, Inc., Chicago, IL) software package (35). Two-tailed P < 0.05 was used to define statistical significance.


   Results
Top
 Abstract
 Introduction
 Subjects and Methods
 Results
Discussion
 References
 
Compliance with treatments, tolerance, and side effects

All patients completing the study had excellent compliance with both dietary and pharmacological treatments, without any significant difference in energy intake or physical activity score between the two groups. Treatments were well tolerated by all of the women. In particular, none reported the appearance of vomiting or of pain, swelling, and blushing at the site of the im injection for the entire period of the study. Three women treated with octreotide reported slight abdominal pain and nausea once during the study compared with none of those receiving placebo (P = 0.216 for abdominal pain and P = 0.147 for nausea in the between-group analysis). Three octreotide-treated patients developed slight diarrhea and complained about flatulence at least once compared with one in the placebo-treated group, but no between-group differences were present (P = 0.588 for both parameters). Moreover, three women in each group reported the appearance of moderate abdominal swelling once during the study (P = 0.563 in the between-group analysis). None developed side effects, including gallstones.

Anthropometry and fat distribution

No significant difference in baseline parameters existed between the two groups (Table 1Go). Body weight, BMI, and TAT values decreased significantly and in a comparable manner from baseline to month 1 in the two groups, without any significant change in the other parameters. Octreotide-LAR-treated, but not placebo-treated, patients also significantly reduced body weight, BMI, waist circumference, and SAT values during the 6-month treatment. However, we found no significant difference in the changes in these parameters after each treatment between the two groups (Table 1Go). In addition, no treatment had a significant effect on waist to hip ratio, TAT, VAT, or the VAT/SAT ratio (Table 1Go).


View this table:
[in this window]
[in a new window]
  		TABLE 1. Anthropometric parameters and indices of body fat distribution (measured by CT scan) (mean ± SD) in PCOS women with abdominal obesity at baseline (B), after 1-month hypocaloric dieting (1st month) and after 6-month combined treatment with hypocaloric diet plus octreotide-LAR or placebo (7th month)

 
Gonadotropins, steroid hormones, and SHBG

Steroid hormones and SHBG concentrations at baseline were comparable in the two groups. No treatment significantly modified serum levels of LH, FSH, FAI, 17-OHP, 17-OHPreg, P, DHEA-S, E2, SHBG, or cortisol. T and A levels significantly decreased in the octreotide-LAR-treated, but not in the placebo-treated, group (Table 2Go). There were no significant differences in the hormonal changes after each treatment between the two groups, although a trend toward greater reductions in T (P = 0.061) and A (P = 0.069) levels was observed in PCOS women treated with octreotide-LAR (Table 2Go).


View this table:
[in this window]
[in a new window]
  		TABLE 2. Gonadotropins, steroid hormones, and SHBG blood concentrations (mean ± SD) in PCOS women with abdominal obesity at baseline (B) and after combined treatment with hypocaloric diet plus octreotide-LAR or placebo (7th month)

 
Glucose, insulin, and insulin resistance indices

Fasting and glucose-stimulated values of glucose and insulin (Fig. 2Go) and the insulin resistance indices (Fig. 3Go) at baseline were not different in the two groups. Fasting and 60-min stimulated glucose values increased with a borderline significance only in the octreotide-LAR group, whereas glucose values at 120 min from the glucose load significantly decreased only in the placebo group. However, no significant changes occurred in the glucose AUC in either group. Fasting insulin significantly decreased in both groups, but a greater reduction was observed in the octreotide-LAR group than in the placebo group (P = 0.018). The 60-min glucose-stimulated insulin values significantly decreased only in the octreotide-LAR group, but no between-group differences were present (P = 0.332). The insulin AUC significantly decreased in the octreotide-LAR group, whereas only a trend toward a reduction was observed in the placebo-treated group (Fig. 2Go). Thus, when changes in insulin AUC were compared between the two groups, a significant difference was found (P = 0.038).



View larger version (21K):
[in this window]
[in a new window]
  		FIG. 2. Fasting and glucose-stimulated glucose and insulin blood concentrations (mean ± SD), as values at different times of the OGTT and as AUC, in PCOS women with abdominal obesity at baseline ({square}) and after combined treatment with hypocaloric diet plus octreotide-LAR or placebo ({blacksquare}). P values refer to the comparison between values at baseline and at the end of the treatment in each group. To convert glucose to millimoles per liter, multiply by 0.056; to convert insulin to picomoles per liter, multiply by 7.17.

 


View larger version (18K):
[in this window]
[in a new window]
  		FIG. 3. Insulin resistance indices (mean ± SD) in PCOS women with abdominal obesity at baseline ({square}) and after combined treatment with hypocaloric diet plus octreotide-LAR or placebo ({blacksquare}). P values refer to the comparison between values at baseline and at the end of the treatment in each group.

 
HOMA significantly decreased and QUICKI significantly increased in both groups, whereas ISI(composite) significantly increased only in the octreotide-LAR-treated group (Fig. 3Go). There were no significant differences in the changes in insulin resistance indices after each treatment between the two groups, apart from a trend toward a greater increment in ISI(composite), with a borderline significance (P = 0.059), after octreotide-LAR administration.

GH, IGF, IGFBPs, and ghrelin

No significant between-group differences in baseline GH, IGF, IGFBPs, or ghrelin levels were observed. GH, IGF-I, and total ghrelin levels significantly decreased, and IGFBP-1, IGFBP-2, and IGFBP-3 significantly increased in the group treated with octreotide-LAR, whereas no significant modifications occurred in the placebo group (Table 3Go). However, compared with placebo, only changes in IGFBP-2, IGFBP-3, and total ghrelin were significantly higher after octreotide-LAR administration (P = 0.042 for IGFBP-2; P = 0.047 for IGFBP-3; P = 0.002 for total ghrelin).


View this table:
[in this window]
[in a new window]
  		TABLE 3. GH, IGF system, and total ghrelin levels (mean ± SD) in PCOS women with abdominal obesity at baseline (B) and after combined treatment with hypocaloric diet plus octreotide-LAR or placebo (7th month)

 
Clinical parameters, menstrual cycles, and ovulation

Because eight of the 11 PCOS patients who were hirsute at baseline were treated with octreotide-LAR and three were given placebo, the pretreatment hirsutism score was significantly higher in the former than in the latter (P = 0.01). All women had acanthosis nigricans, and both groups had a similar score at baseline. After treatment, the hirsutism and acanthosis nigricans scores significantly decreased only in the octreotide-LAR group (Table 4Go). The greater effect of octreotide-LAR with respect to placebo was confirmed when the changes that occurred in these two parameters were compared between the two groups (P = 0.004 for hirsutism score; P = 0.008 for acanthosis nigricans score).


View this table:
[in this window]
[in a new window]
  		TABLE 4. Clinical data (mean ± SD) and ovulation in PCOS women with abdominal obesity at baseline (B) and after combined treatment with hypocaloric diet plus octreotide-LAR or placebo (7th month)

 
Menstrual cyclicity at baseline was similar in the two groups, and it significantly and similarly improved after treatments in both groups (Table 4Go). Anovulation was present during the first posttreatment menstrual cycle in all women. Conversely, during the last treatment cycle, ovulation occurred in all patients treated with octreotide-LAR, but in only one of those given placebo (Table 4Go). Overall ovulatory rates were therefore significantly higher during octreotide-LAR than placebo treatment (P < 0.001). The hormonal profile assessed in the first and last treatment cycles of each group is shown in Fig. 4Go. Both groups had a similar hormonal profile at the first cycle, apart from FSH levels on d 28, which were significantly higher in the octreotide-LAR group than in the placebo group. However, significant differences appeared between the two groups at the last treatment cycle. In particular, P was significantly higher in the octreotide-LAR group than in the placebo group on both d 21 and 28 of the menstrual cycle. Moreover, the octreotide-LAR-treated group showed higher levels of LH and E2 and lower levels of FSH than the placebo group on d 28. The overall profiles of LH, FSH, E2, and P did not significantly change during the first treatment cycle for either group. Conversely, significant increases in E2 (P = 0.049) and P (P = 0.012) and a significant decrease in FSH (P = 0.023) were observed only in the octreotide-LAR group in the last treatment cycle. No significant overall modifications occurred in the LH profile in either group. Compared with the effects of placebo, only changes in E2 and P were persistently significantly higher after octreotide-LAR administration (P = 0.044 for E2; P = 0.009 for P).



View larger version (49K):
[in this window]
[in a new window]
  		FIG. 4. Serum LH, FSH, E2, and P concentrations (mean ± SE) at 7, 14, 21, and 28 d after start of menstrual bleeding in the first (top panels) and last (bottom panel) menstrual cycles during treatments with hypocaloric diet plus octreotide-LAR ({blacksquare}) or placebo ({square}). P values refer to the comparison between the two groups at the reference time. To convert E2 to picomoles per liter, multiply by 3.67; to convert P to nanomoles per liter, multiply by 3.18.

 
One woman in the octreotide-LAR group conceived spontaneously in the second cycle after discontinuing treatment and successfully completed an uneventful singleton gestation.


   Discussion
Top
 Abstract
 Introduction
 Subjects and Methods
 Results
 Discussion
References
 
This is the first report of the effect and safety features of long-term treatment with octreotide-LAR in dieting abdominally obese women with PCOS. We found that the addition of octreotide-LAR significantly amplified the effects of a low-calorie diet; fasting and glucose-stimulated insulin levels; insulin resistance; and androgen, GH, and IGF-I concentrations were reduced, whereas circulating IGFBP levels were increased by octreotide-LAR. This treatment also significantly improved hirsutism and acanthosis nigricans. The menstrual pattern appeared to improve in a similar manner in both groups; however, compared with the effect in placebo-treated women, octreotide-LAR demonstrated a particularly strong efficacy in improving the ovulatory rate. Conversely, octreotide-LAR administration did not additionally improve the positive effects on body composition and fat distribution of a low-calorie diet. This result partly confirms our previous reports (25, 36) showing that changes in body composition mainly depend on diet and that they are only marginally improved when insulin sensitivity and hyperandrogenemia are further corrected by the administration of insulin-sensitizing (36) and antiandrogenic (25) drugs in dieting obese PCOS women. Interestingly, octreotide-LAR administration was more effective than placebo in reducing fasting and glucose-stimulated insulin levels and in improving ISI (composite) and thus insulin resistance. This finding is consistent with the previously reported efficacy of octreotide-LAR to directly influence insulin secretion (9, 37) and thus with its potential role as an insulin-sensitizing agent. The ability of octreotide to decrease pancreatic insulin release in addition to improving peripheral insulin sensitivity may explain the marginal effect on glucose tolerance we observed in the octreotide-LAR-treated PCOS patients in the current study. Although previous studies reported the occurrence of some degree of glucose intolerance after treatment with octreotide, this effect may be dependent on the use of higher doses of octreotide (37).

As expected, octreotide-LAR reduced circulating GH levels, and this can be explained by its well-known ability to inhibit pituitary GH secretion and GHRH hypothalamic release (38). In contrast, the significant and selective decrease in circulating ghrelin, the most important endogenous GH secretagogue, may represent an additional mechanism to explain the inhibitory effect of octreotide-LAR on the GH/IGF-I system, as reported in previous studies (39). Octreotide-LAR also significantly increased IGFBP-1, IGFBP-2, and IGFBP-3, thus favoring a decrease in free IGF-I levels and, therefore, in IGF-I availability to the target tissues. We speculated that combined reduction of insulin and IGF-I levels may represent the key mechanism responsible for the decrement in androgen levels we found in PCOS patients treated with octreotide-LAR, because no direct effects of somatostatin or its analogs on ovarian steroidogenesis have been demonstrated to date (40). Our data also indirectly support the concept that octreotide-LAR did not affect adrenal steroidogenesis, because no significant changes in cortisol and DHEA-S concentrations occurred during the study. Unexpectedly, we found that octreotide-LAR had no effect on LH levels, a finding that contradicts other clinical studies in PCOS women (12, 13, 15, 16, 18, 19). However, previous studies examined integrated LH concentrations after frequent blood sampling (12, 13) or LH responsiveness to GnRH agonist (16), whereas we performed only single fasting LH measurements; this methodological approach may have limited our ability to assess variations in LH secretion. Furthermore, in contrast with all other published studies, in which normal weight or moderately obese PCOS women were examined, we mainly assessed frankly obese PCOS women with an abdominal phenotype, a condition characterized by lower and sometimes virtually normal LH levels (2).

Octreotide-LAR also had evident clinical effects, because it significantly improved hirsutism and acanthosis nigricans, probably related to the efficacy of octreotide in reducing hyperandrogenemia and in improving insulin resistance and hyperinsulinemia. A novel feature of this study was the strong effect exerted by octreotide-LAR on the ovulatory status of PCOS women, which appeared to be relatively independent from changes in menstrual cyclicity. Our finding that menstrual cycle patterns improved similarly in both octreotide-LAR and placebo groups suggests that weight loss and energy restriction were probably the major factors responsible for this effect. The lack of an increase in P in the last menstrual cycle of the study, found in all but one woman in the placebo group, indicates that anovulation persisted in these subjects. Conversely, all women receiving octreotide-LAR ovulated at the end of treatment despite limited changes in serum gonadotropin levels. The presence of somatostatin receptors in human granulosa-luteal cells and human follicles makes it conceivable that octreotide-LAR affects the ovulatory process through a direct action at the ovarian level (11). This process may particularly involve all mechanisms dependent on regulation of the insulin-IGF system, including IGFBP action. In particular, although the action of IGFBPs in the modulation of ovarian function, such as follicular growth, recruitment, and atresia, and hormone biosynthesis is not well known (5), it is likely that changes in their circulating concentrations and intraovarian functions are important to explain the good performance of octreotide-LAR to increase ovulation in abdominal obese PCOS.

Potential limitations of this study include the single-blind design, which is only partially compensated by the careful criteria of selection and randomization of the patients and by the fact that the investigator assessing the outcomes was blinded to treatment assignment. Therefore, additional, larger, double-blinded trials are needed to confirm the clinical relevance of our findings.

In conclusion, this study shows that long-term administration of octreotide-LAR had several benefits on the clinical, metabolic, and hormonal parameters of dieting abdominal obese PCOS women, and that it was able to restore ovulatory status in otherwise anovulatory patients. This treatment seems to be safe and well tolerated, thus providing the basis for a novel application of octreotide-LAR in the treatment of hormonal dysfunction and infertility in PCOS women.


   Acknowledgments
 
We are indebted to Novartis Farma S.p.A. (Origgio-Varese, Italy), who provided both octreotide-LAR and octreotide. We thank Dr. Anastasia Carcello for performing the CT scans, Dr. A. M. Morselli-Labate for statistical analysis, and Ms. Susan West for reviewing the English language of the manuscript.


   Footnotes
 
First Published Online April 12, 2005

1 Deceased, September 2004, in Genova, Italy. Back

Abbreviations: A, Androstenedione; AUC, area under the curve; BMI, body mass index; CT, computerized tomography; DHEA-S, dehydroepiandrosterone sulfate; E2, estradiol; FAI, free testosterone; HOMA, homeostasis model assessment; IGFBP, IGF-binding protein; ISI(composite), insulin sensitivity index during the OGTT; OGTT, oral glucose tolerance test; 17-OHP, 17-hydroxyprogesterone; 17-OHPreg, 17-hydroxypregnenolone; P, progesterone; PCOS, polycystic ovary syndrome; QUICKI, quantitative insulin-sensitivity check index; SAT, sc adipose tissue; T, testosterone; TAT, total adipose tissue; VAT, visceral adipose tissue.

Received December 17, 2004.

Accepted April 6, 2005.


   References
Top
 Abstract
 Introduction
 Subjects and Methods
 Results
 Discussion
 References
 

  1. Rotterdam ESHRE/ASMR-Sponsored PCOS Consensus Workshop Group 2004 Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Hum Reprod 19:41–47[Abstract/Free Full Text]
  2. Gambineri A, Pelusi C, Vicennati V, Pagotto U, Pasquali R 2002 Obesity and the polycystic ovary syndrome. Int J Obes Rel Metab Disord 26:883–896[CrossRef][Medline]
  3. Fulghesu AM, Villa P, Pavone V, Guido M, Apa R, Caruso A, Lanzone A, Rossodivita A, Mancuso S 1997 The impact of insulin secretion on the ovarian response to exogenous gonadotropins in polycystic ovary syndrome. J Clin Endocrinol Metab 82:644–648[Abstract/Free Full Text]
  4. Franks S 2003 Assessment and management of anovulatory infertility in polycystic ovary syndrome. Endocrinol Metab Clin North Am 32:639–651[CrossRef][Medline]
  5. Poretsky L, Cataldo NA, Rosenwaks Z, Giudice LC 1999 The insulin-related ovarian regulatory system in health and disease. Endocr Rev 20:535–582[Abstract/Free Full Text]
  6. Morales AJ, Laughlin GA, Bützow T, Maheshwari H, Baumann G, Yen SSC 1996 Insulin, somatotropic, and luteinizing hormone axes in lean and obese women with polycystic ovary syndrome: common and distintict features. J Clin Endocrinol Metab 81:2854–2864[Abstract/Free Full Text]
  7. Chiodera P, Volpi R, D’ Amato L, Fatone M, Cicarini C, Faia A, Caiazza A, Rossi G, Coiro V 1986 Inhibition by somatostatin of LHRH-induced LH release in normal mestruating women. Gynecol Obstet Invest 22:17–21[CrossRef][Medline]
  8. Brazaan JC, Vale W, Burgus N, Lang N, Buteler M, Gullemin R 1973 Hypothalamic polypeptide that inhibits the secretion of immunoreactive pituitary growth hormone. Science 179:77–79[Abstract/Free Full Text]
  9. Hsu WH, Xiang HD, Rajan AS, Kunze DL, Boyd III AE 1991 Somatostatin inhibits insulin secretion by a G-protein-mediated decrease in Ca2+ entry through voltage-dependent Ca2+ channels in the ß-cell. J Biol Chem 266:837–843[Abstract/Free Full Text]
  10. Patel YC, Murthy KK, Escher EE, Banville D, Spiess J, Srikant CB 1990 Mechanism of action of somatostatin: an overview of receptor function and studies of the molecular characterization and purification of somatostatin receptor protein. Metabolism 39:63–69[CrossRef][Medline]
  11. Strass MC, Seelig AS, Weiss JM, Diedrich K, Ortmenn O Expression of somatostatin and its receptors in human ovary. Proc 19th Annual Meeting of the European Society for Human Reproduction & Embryology, Madrid, Spain, 2003 (Abstract P-495)
  12. Prevelic GM, Wurzburger MI, Balin-Peric L, Nesic JS 1990 Inhibitory effect of sandostatin on secretion of luteinizing hormone and ovarian steroids in polycystic ovary syndrome. Lancet 336:900–903[CrossRef][Medline]
  13. Prevelic GM, Wurzburger MI, Balin-Peric L, Hardiman P, Okolo S, Maletic D, Ginsburg J 1992 Effects of the somatostatin analogue, octreotide, in polycystic ovary syndrome. Metabolism 41:76–79[Medline]
  14. Prevelic GM, Ginsburg J, Maletic D, Hardiman P, Okolo S, Balin-Peric L, Thomas M, Orskov H 1995 The effects of the somatostatin analogue octreotide on ovulatory performance in women with polycystic ovaries. Hum Reprod 10:28–32[Abstract/Free Full Text]
  15. Morris RS, Carmina E, Vijod MA, Stanczyk FZ, Lobo RA 1995 Alterations in the sensitivity of serum insulin-like growth factor 1 and insulin-like growth factor binding protein-3 to octreotide in polycystic ovary syndrome. Fertil Steril 63:742–746[Medline]
  16. Fulghesu AM, Lanzone A, Andreani CL, Pierro E, Caruso A, Mancuso S 1995 Effectiveness of a somatostatin analogue in lowering luteinizing hormone and insulin-stimulated secretion in hyperinsulinemic women with polycystic ovary disease. Fertil Steril 64:703–708[Medline]
  17. Morris RS, Karande VC, Dudkiewicz A, Morris JL, Gleicher N 1999 Octreotide is not useful for clomiphene citrate resistance in patients with polycystic ovary syndrome but may reduce the likelihood of ovarian hyperstimulation syndrome. Fertil Steril 71:452–456[CrossRef][Medline]
  18. Lidor A, Soriano D, Seidman DS, Dor J, Mashiach S, Rabinovici J 1998 Combined somatostatin analog and follicle-stimulating hormone for women with polycystic ovary syndrome resistant to conventional treatment. Gynecol Endocrinol 12:97–101[Medline]
  19. Ciotta L, De Leo V, Galvani F, La Marca A, Cianci A 1999 Endocrine and metabolic effects of octreotide, a somatostatin analogue, in lean PCOS patients with either hyperinsulinemia or normoinsulinemia. Hum Reprod 14:2951–2958[Abstract/Free Full Text]
  20. Wenzl R, Lehner R, Schurz B, Karas H, Huber JC 1996 Successful ovulation induction by sandostatin-therapy of polycystic ovarian disease. Acta Obstet Gynecol Scand 75:298–299[Medline]
  21. Gillis JC, Noble S, Goa KL 1997 Octreotide long-acting release (LAR). A review of its pharmacological properties and therapeutic use in the management of acromegaly. Drugs 53:681–699[Medline]
  22. World Health Organization 1997 Preventing and managing the global epidemic. report of a WHO consultation on obesity. Geneva: World Health Organization; WHO/NUT/NCD/98.1
  23. Nestler JE, Jakubowicz DJ, Evans WS, Pasquali R 1998 Effects of metformin on spontaneous and clomiphene-induced ovulation in the polycystic ovary syndrome. N Engl J Med 338:1876–1880[Abstract/Free Full Text]
  24. Ferriman D, Gallwey JD 1961 Clinical assessment of body hair growth in women. J Clin Endocrinol Metab 21:1440–1447
  25. Gambineri A, Pelusi C, Genghini S, Morselli-Labate AM, Cacciari M, Pagotto U, Pasquali R 2004 Effect of flutamide and metformin administered alone or in combination in dieting obese women with polycystic ovary syndrome. Clin Endocrinol (Oxf) 60:241–249[CrossRef][Medline]
  26. Hud JA, Cohen JB, Wagner JM, Cruz PD 1992 Prevalence and significance of acanthosis nigricans in an adult obese population. Arch Dermatol 128:941–944[Abstract/Free Full Text]
  27. Baecke JAH, Burema J, Frijters JER 1982 A short questionnaire for the measurement of habitual physical activity in epidemiological studies. Am J Clin Nutr 36:939–942
  28. Pasquali R, Gambineri A, Anconetani B, Vicennati V, Colitta D, Caramelli E, Casimirri F, Morselli-Labate AM 1999 The natural history of the metabolic syndrome in young women with the polycystic ovary syndrome and the effect of long-term oestrogen-progestagen treatment. Clin Endocrinol (Oxf) 50:517–527[CrossRef][Medline]
  29. Garrone S, Radetti G, Sidoti M, Bozzola M, Minuto F, Barreca A 2002 Increased insulin-like growth factor (IGF)-II and IGF/IGF-binding protein ratio in prepubertal constitutionally tall children. J Clin Endocrinol Metab 87:5455–5460[Abstract/Free Full Text]
  30. Pagotto U, Gambineri A, Vicennati V, Heiman ML, Tschöp M, Pasquali R 2002 Plasma ghrelin, obesity, and the polycystic ovary syndrome: correlation with insulin resistance and androgen levels. J Clin Endocrinol Metab 87:5625–5629[Abstract/Free Full Text]
  31. Vermeulen A, Verdonck L, Kaufman JM 1999 A critical evaluation of simple methods for the estimation of free testosterone in serum. J Clin Endocrinol Metab 84:3666–3672[Abstract/Free Full Text]
  32. Matthews DR, Hosker JP, Rudenski AS, Nylor BA, Treacher DF, Turner RC 1985 Homeostasis model assessment: insulin resistance and ß-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28:412–419[CrossRef][Medline]
  33. Matsuda M, De Fronzo RA 1999 Insulin sensitivity indices obtained from oral glucose tolerance testing. Diabetes Care 22:1462–1470[Abstract/Free Full Text]
  34. Mather KJ, Hunt AE, Steinberg HO, Paradisi G, Hook G, Katz A, Quon MJ, Baron AD 2001 Repeatability characteristics of simple indices of insulin resistance: implications for research applications. J Clin Endocrinol Metab 86:5457–5464[Abstract/Free Full Text]
  35. Norusis MJ 1990 SPSS/PC+ 4.0 base and advanced statistics manuals. Chicago: SPSS
  36. Pasquali R, Gambineri A, Biscotti D, Vicennati V, Gagliardi L, Colitta D, Fiorini S, Cognini GE, Filicori M, Morselli-Labate AM 2000 Effect of long-term treatment with metformin added to hypocaloric diet on body composition, fat distribution, and androgen and insulin levels in abdominally obese women with and without the polycystic ovary syndrome. J Clin Endocrinol Metab 85:2767–2774[Abstract/Free Full Text]
  37. Bertoli A, Magnaterra R, Bordoni P, Marini MA, Barini A, Fusco A, Bollea MR 1996 Dose-dependent effect of octreotide on insulin secretion after OGTT in obesity. Horm Res 49:17–21[CrossRef]
  38. Giustina A, Veldhuis JD 1998 Pathophysiology of the neuroregulation of growth hormone secretion in experimental animals and the human. Endocr Rev 19:717–797[Abstract/Free Full Text]
  39. Barkan AL, Dimaraki EV, Jessup SK, Symons KV, Ermolenko M, Jaffe CA 2003 Ghrelin secretion in humans is sexually dimorphic, suppressed by somatostatin, and not affected by the ambient growth hormone levels. J Clin Endocrinol Metab 88:2180–2184[Abstract/Free Full Text]
  40. Pawelezyk LA, Duleba AJ, Moon Ys, Yuen BH 1993 Sandostatin has no direct effect on ovarian steroidogenesis in vitro. Hum Reprod 8:346–368



This article has been cited by other articles:


Home page
 J. Clin. Endocrinol. Metab.Home page
E. Codner and H. F. Escobar-Morreale
Hyperandrogenism and Polycystic Ovary Syndrome in Women with Type 1 Diabetes Mellitus
J. Clin. Endocrinol. Metab., April 1, 2007; 92(4): 1209 - 1216.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
A. Gambineri, L. Patton, A. Vaccina, M. Cacciari, A. M. Morselli-Labate, C. Cavazza, U. Pagotto, and R. Pasquali
Treatment with Flutamide, Metformin, and Their Combination Added to a Hypocaloric Diet in Overweight-Obese Women with Polycystic Ovary Syndrome: A Randomized, 12-Month, Placebo-Controlled Study
J. Clin. Endocrinol. Metab., October 1, 2006; 91(10): 3970 - 3980.
[Abstract] [Full Text] [PDF]

Home page
 Eur J EndocrinolHome page
R. Pasquali and A. Gambineri
Insulin-sensitizing agents in polycystic ovary syndrome.
Eur. J. Endocrinol., June 1, 2006; 154(6): 763 - 775.
[Abstract] [Full Text] [PDF]

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Submit a related Letter to the Editor
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Gambineri, A.
Right arrow Articles by Pasquali, R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Gambineri, A.
Right arrow Articles by Pasquali, R.
Related Collections
Right arrow Female Endocrinology
Right arrow Obesity

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Endocrinology Endocrine Reviews J. Clin. End. & Metab.
Molecular Endocrinology Recent Prog. Horm. Res. All Endocrine Journals